AstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in...
Source LinkAstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in...
Source Link
Comments